Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses the challenges in identifying predictive markers of response to immune checkpoint inhibitors in triple-negative breast cancer (TNBC). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.